Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Rein Therapeutics (RNTX) Equity Average (2017 - 2025)

Rein Therapeutics filings provide 9 years of Equity Average readings, the most recent being $31.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 57.82% year-over-year to $31.6 million, compared with a TTM value of $31.6 million through Dec 2025, down 57.82%, and an annual FY2025 reading of $35.7 million, down 53.3% over the prior year.
  • Equity Average hit $31.6 million in Q4 2025 for Rein Therapeutics, down from $47.1 million in the prior quarter.
  • The five-year high for Equity Average was $98.1 million in Q3 2024, with the low at $12.0 million in Q3 2023.
  • Median Equity Average over the past 5 years was $47.1 million (2021), compared with a mean of $47.7 million.
  • The sharpest move saw Equity Average tumbled 58.89% in 2023, then surged 717.99% in 2024.
  • Year by year, Equity Average stood at $47.0 million in 2021, then crashed by 56.05% to $20.7 million in 2022, then soared by 165.0% to $54.7 million in 2023, then surged by 36.65% to $74.8 million in 2024, then plummeted by 57.82% to $31.6 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $31.6 million, $47.1 million, and $48.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.